STK-002 is under clinical development by Stoke Therapeutics and currently in Phase I for Unspecified Ophthalmological Disorders. According to GlobalData, Phase I drugs for Unspecified Ophthalmological Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the STK-002 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STK-002 overview
STK-002 is under development for the treatment of autosomal dominant optic atrophy (ADOA). It acts by targeting the OPA1 mitochondrial dynamin-like GTPase. The drug candidate is developed based on TANGO (Targeted Augmentation of Nuclear Gene Output) platform technology. TANGO exploits non-productive splicing events to effect targeted enhancement of gene expression. It is administered through intravitreal route of administration.
Stoke Therapeutics overview
Stoke Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based medicines to address the underlying causes of severe diseases. The company’s main activity focuses on the use of its proprietary research platform, targeted augmentation of nuclear gene output (TANGO), to upregulate protein expression and restore missing proteins. The company’s lead clinical program focuses on Dravet syndrome, a severe and progressive genetic epilepsy. Stoke’s products are primarily aimed at patients suffering from severe diseases caused by genetic mutations. The company’s pipeline products address the diseases of dgavet syndrome and autosomal dominant optic atrophy. Stoke Therapeutics is headquartered in Bedford, Massachusetts, the US.
For a complete picture of STK-002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
